<code id='392D6672CB'></code><style id='392D6672CB'></style>
    • <acronym id='392D6672CB'></acronym>
      <center id='392D6672CB'><center id='392D6672CB'><tfoot id='392D6672CB'></tfoot></center><abbr id='392D6672CB'><dir id='392D6672CB'><tfoot id='392D6672CB'></tfoot><noframes id='392D6672CB'>

    • <optgroup id='392D6672CB'><strike id='392D6672CB'><sup id='392D6672CB'></sup></strike><code id='392D6672CB'></code></optgroup>
        1. <b id='392D6672CB'><label id='392D6672CB'><select id='392D6672CB'><dt id='392D6672CB'><span id='392D6672CB'></span></dt></select></label></b><u id='392D6672CB'></u>
          <i id='392D6672CB'><strike id='392D6672CB'><tt id='392D6672CB'><pre id='392D6672CB'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:comprehensive    - browse:3116
          Alastair Grant/AP

          LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

          The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

          advertisement

          AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus